A detailed history of Sittner & Nelson, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Sittner & Nelson, LLC holds 3,737 shares of CRSP stock, worth $192,903. This represents 0.08% of its overall portfolio holdings.

Number of Shares
3,737
Previous 3,547 5.36%
Holding current value
$192,903
Previous $191,000 8.38%
% of portfolio
0.08%
Previous 0.1%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

BUY
$44.62 - $62.75 $8,477 - $11,922
190 Added 5.36%
3,737 $175,000
Q2 2024

Aug 13, 2024

SELL
$51.17 - $68.18 $15,351 - $20,454
-300 Reduced 7.8%
3,547 $191,000
Q1 2024

May 10, 2024

BUY
$60.67 - $89.12 $15,167 - $22,280
250 Added 6.95%
3,847 $262,000
Q4 2023

Feb 12, 2024

SELL
$38.62 - $72.18 $3,475 - $6,496
-90 Reduced 2.44%
3,597 $225,000
Q3 2023

Nov 13, 2023

BUY
$45.39 - $59.0 $6,808 - $8,850
150 Added 4.24%
3,687 $167,000
Q1 2023

May 09, 2023

BUY
$41.0 - $56.12 $5,330 - $7,295
130 Added 3.82%
3,537 $159,000
Q4 2022

Feb 01, 2023

SELL
$39.19 - $65.67 $783 - $1,313
-20 Reduced 0.58%
3,407 $138,000
Q1 2022

May 10, 2022

BUY
$53.19 - $79.24 $37,233 - $55,468
700 Added 25.67%
3,427 $215,000
Q4 2021

Feb 09, 2022

BUY
$70.09 - $111.29 $14,718 - $23,370
210 Added 8.34%
2,727 $207,000
Q3 2021

Nov 12, 2021

BUY
$110.2 - $156.64 $97,747 - $138,939
887 Added 54.42%
2,517 $282,000
Q2 2021

Aug 12, 2021

BUY
$100.84 - $161.89 $43,361 - $69,612
430 Added 35.83%
1,630 $264,000
Q1 2021

May 06, 2021

BUY
$110.72 - $210.04 $132,864 - $252,048
1,200 New
1,200 $146,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $4.03B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Sittner & Nelson, LLC Portfolio

Follow Sittner & Nelson, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sittner & Nelson, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sittner & Nelson, LLC with notifications on news.